glp-1 agonist prediabetes New Guidelines for Type 2 Diabetes in 2025 Is GLP-1 Safe for Weight

Prior drug treatments included antihyperlipidemic agents, antidiabetic agents, antiplatelet agents, antihypertensives, and other anti-obesity agents dispensed up to 24 months before the first dispensation of any GLP-1 RA

Meanwhile, Eli Lilly is gearing up to introduce orforglipron calcium, which is expected to hit the market by 2026

Under the brand name Zepbound, it's approved to treat obesity, while under the brand name Mounjaro, it's approved to treat type 2 diabetes

The appetite suppression and delayed gastric emptying contribute to significant weight loss, which has expanded their clinical applications beyond diabetes management

This guide walks through how these drugs work, which patients benefit, what the trial data actually show, what to expect in terms of side effects and cost, and the difficult question of what happens when you stop

Arvanitakis K, Koufakis T, Popovic D, et al